A HA! 2)
RBC Capital Markets started coverage of Jasper Therapeutics (NASDAQ:JSPR) with an outperform rating, citing the company's potential to access the $100B+ mast cell disease market.7 mins ago
On Thursday, RBC Capital initiated coverage on Jasper Therapeutics (NASDAQ:JSPR), assigning an...